Covered by taxable income — not by the quarter's NII. For the fiscal first quarter ended June 30, 2026, pre-tax net investment income was $0.57 a share against $0.64 total declared — a $0.58 regular dividend plus a $0.06 supplemental — a 112% payout on the quarter's earnings, and 102% on the regular dividend alone. The declared total is not paid out of principal on a taxable-income basis: estimated undistributed taxable income stood at $0.87 a share at quarter-end. But the quarterly earnings did not cover the quarterly payout, so the supplemental depends on that stockpile lasting, and on realized gains refilling it. NAV slipped to $16.61 from $16.69, on $10.9 million of net depreciation, while non-accruals stayed low at 1.1% of the portfolio at fair value and 99% of the credit book is first-lien senior secured.
Key risk: Middle-market credit plus a supplemental that outruns quarterly earnings — if NII stays below the $0.64 total, the $0.87 undistributed-taxable-income cushion drains instead of refilling, and the supplemental is the first thing that goes.
Changes if: Pre-tax NII stays below the $0.64 total for more than a quarter or two, undistributed taxable income falls materially, or non-accruals rise from 1.1% at fair value. Together those would point to a payout set above what the portfolio earns each quarter.
- !NII coverage check: First fiscal quarter 2027 pre-tax NII of $0.57 a share did not cover the $0.64 total declared — the gap is carried by $0.87 a share of undistributed taxable income, a stockpile, not a quarterly run-rate.
- !Yield check: 10.4% on the regular dividend alone — 11.4% including the supplemental — is pay for middle-market credit risk, and at $22.37 the shares sit at a premium to the $16.61 NAV, so the yield is not bought at a discount.
- !NAV trend check: NAV per share slipped from $16.69 to $16.61 in the quarter, down about 0.5%, on $10.9 million of net realized and unrealized depreciation — small, but in the wrong direction while the payout exceeds NII.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.